| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (groß) | News + Adhoc | Bilanz/GuV | Termine | Zertifikate | Depot |
| Times + Sales | Chart-Analyse | Analysen | Dividende/HV | Profil | Optionsscheine | Watchlist |
| Börsenplätze | Chartvergleich | Kursziele | Vergleich | Insidertrades | Knock-outs | myfinanzen |
| Orderbuch | Realtime Stuttgart | RSS Feed | Analyse | im Forum | Fonds | Senden |
| Historisch | Realtime Push | IR-Daten | Anleihen | handeln | ||
| Analyst | Buy | Hold | Sell | Kursziel* | Abstand | Datum |
|---|---|---|---|---|---|---|
| UBS AG | 61,00$ | +13,49% | 06.02.12 | |||
| Robert W. Baird & Co. Incorporated | 60,00$ | +11,63% | 06.02.12 | |||
| RBC Capital Markets | 60,00$ | +11,63% | 06.02.12 | |||
| Deutsche Bank Securities | 66,00$ | +22,79% | 06.02.12 | |||
| Needham & Company, LLC | 54,00$ | +0,47% | 03.02.12 | |||
| Credit Suisse Group | 42,00$ | -21,86% | 12.12.11 | |||
| Piper Jaffray & Co. | 52,00$ | -3,26% | 01.12.11 | |||
| Goldman Sachs Group Inc. | 46,00$ | -14,42% | 30.11.11 | |||
| Citigroup Corp. | 49,00$ | -8,84% | 30.11.11 | |||
| Der Aktionär | 35,00€ | - | 06.10.11 | |||
| JP Morgan Chase & Co. | 50,00$ | -6,98% | 17.08.11 | |||
| Barclays Capital | 47,00$ | -12,56% | 18.04.11 |
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| AstraZeneca plc | 2 | 7 | 5 | 29,64 £ | -0,50% |
| Gilead Sciences Inc. | 9 | 3 | 0 | 53,36 $ | -0,73% |
| GlaxoSmithKline plc (GSK) | 6 | 8 | 2 | 14,48 £ | +2,62% |
| Merck Co. | 2 | 3 | 0 | 38,50 $ | +1,66% |
| Merck KGaA | 5 | 14 | 2 | 74,45 € | -8,76% |
| Novartis AG | 11 | 6 | 2 | 56,62 | +10,59% |
| Pfizer Inc. | 6 | 4 | 1 | 23,33 $ | +11,10% |
| Roche Holding AG (Genussschein) | 0 | 0 | 0 | - | - |
| Roche Holding AG (Inhaberaktie) | 11 | 4 | 0 | 166,27 | -2,14% |
| STADA Arzneimittel AG (vink. NA) | 13 | 8 | 1 | 24,32 € | +6,85% |